Search PubMed⌕ Search

Biomedical subjects

A Lussier

Publications and source records attributed to A Lussier.

At least 73 records · Page 4Linked to original sources
PubMed1977

[An unusual dissecting cyst of the knee in a patient with rheumatoid arthritis].

An unusual synovial cyst of the knee in rheumatoid arthritis is reported. The communication with the knee joint anteriorly under the tibial insertion of the internal collateral ligament is in contrast with all the cases reported to date in the literature. The advantages of the air arthrogram (coupled with the arteriography) over the opaque contrast medium arthrography are shown to be superior for such special case.

Arthritis, Rheumatoid↗
PubMed1976

Gastro-intestinal microbleeding under acetylsalicylic acid, ketoprofen and placebo.

A quantitative comparison of gastro-intestinal microbleeding induced by acetylsalicylic acid (ASA), 3.6 g daily, ketoprofen (KETO), 200 mg daily and placebo (P) was undertaken in 12 normal volunteers using a double-blind factorial design with repeated measures. We conclude that KETO induces less gastro-intestinal bleeding than ASA but more than placebo and that there is a significant residual bleeding under placebo following ASA.

Anti-Inflammatory Agents↗
PubMed1976

Gastrointestinal microbleeding in normal subjects receiving acetylsalicylic acid, placebo, and R-803, a new antiinflammatory agent, in a design balanced for residual effects.

This study was undertaken to compare the relative gastrointestinal toxicity of equipotent doses of acetylsalicylic acid (ASA), 900 MG q.i.d., and a new anti-inflammatory agent, R-803, 300 mg q.i.d., against placebo. Gastrointestinal micro-bleeding was quantitated with the 61Cr-labeled erythrocyte assay. The experimental design was balanced for residual effects in the first week following any treatment. An interesting relationship between stool weight and blood loss was found to influence the microbleeding independently of the treatments themselves. All observed blood loss values were corrected by regression to a reference stool weight of 100 Gm. Final analysis of corrected values was done on arithmetic and logarithmic scales. On both scales, R-803 induced much less blood loss than ASA. A difference of 1.3 ml/day between R-803 and placebo was not statistically significant on the arithmetic scale. On the log scale, a statistically significant difference was found; but since it corresponds to 0.4 ml/day, it was not considered to be clinically significant at this dosage.

Anti-Inflammatory Agents↗
PubMed1976

[Synovial fluid. Review of international literature from 1972 to 1975 (author's transl)].

The tremendous increase in the number of articles from the world scientific literature dealing with the synovial fluid in recent years, reflects the growing interest of research on that subject. The current review summarizes the scientific works published during the period of 1972 to 1975. This review deals with fundamental as well as applied research or clinical reports adding some diagnostic hints in the knowledge of diseases involving joints. The content of the review is divided in two major chapters. 1) The Physico-Chemical Properties of the Synovial Fluid (viscosity, pH,...); 2) The Composition of the Synovial Fluid (proteins, carbohydrates, lipids, prostaglandins, cells, crystals, micro-organisms).

Antibodies, Antinuclear↗
PubMed1976

Gastrointestinal blood loss induced by ketoprofen, aspirin and placebo (preliminary report).

In a 4-week double-blind multi-crossover trial 12 healthy volunteers received 1-week treatment with aspirin (3.6 g daily) and 1-week treatment with ketoprofen (200 mg daily). Before and after each active drug treatment the volunteers received 1-week of placebo treatment. The gastrointestinal blood loss was quantitatively determined by use of the radioactive chromiun (Cr51) technique. It is concluded that the gastrointestinal blood loss during the ketoprofen treatment was significantly less than during the aspirin period but significantly greater than during the placebo periods.

Adult↗
PubMed1976

A double-blind cross-over evaluation of ketoprofen and aspirin in rheumatoid arthritis.

Thirty rheumatoid patients participated in a 6-week double-blind cross-over assessment of ketoprofen (200 mg daily) and aspirin (3.6 g daily). Regular clinical and laboratory assessments were conducted and revealed that at the dosages employed, the two drugs exerted a statistically comparable therapeutic effect. Side-effects were more frequent with aspirin. Ketoprofen was preferred more often by the patients while the investigator found it acceptable as often as aspirin.

Adult↗
PubMed1975

Scientific methodology applied.

The subject of this symposium is naproxen, a new drug that resulted from an investigation to find a superior anti-inflammatory agent. It was synthesized by Harrison et al. in 1970 at the Syntex Institute of Organic Chemistry and Biological Sciences. How can we chart the evolution of this or any other drug? Three steps are necessary: first, chemical studies (synthesis, analysis); second, animal pharmacology; third, human pharmacology. The last step can additionally be divided into four phases: metabolism and toxicology of the drug in normal volunteers; dose titration and initial clinical trials with sick subjects (pharmacometry); confirmatory clinical trials when the drug is accepted on the market and revaluation (familiarization trials). To discover the truth about naproxen, we must all participate actively with a critical mind, following the principles of scientific methodology. We shall find that the papers to be presented today all deal with the third step in the evaluation process--clinical pharmacology. It is quite evident that the final and most decisive test must be aimed at the most valuable target: the human being. The end product of this day's work for each of us should be the formation of an opinion based on solid scientific proofs. And let us hope that we will all enjoy fulfilling the symposium in its entire etymological meaning this evening. In vino veritas.

Animals↗
PubMed1975

Naproxen: long-term study in rheumatoid arthritis and "placebo pulse".

Naproxen is by now a relatively well-known antirheumatic drug, and many short-term studies have shown its efficacy and relatively good tolerance. We have observed 64 patients with definite or classical rheumatoid disease, 27 of whom have been followed for well over two years on daily doses of naproxen to ascertain the persistence of drug efficacy and safety. In this part of our study, patients were subjected to complete clinical and biochemical evaluations at two-monthly intervals. Naproxen was well tolerated, and the few side effects reported were transient and mild in nature. Sequential laboratory studies revealed no significant anomaly. Clinical evaluation showed no pattern suggestive of decreasing antirheumatic activity. A question frequently encountered in the treatment of certain diseases such as rheumatoid arthritis is whether long-term improvement is due to efficacious suppressive therapy or spontaneous abatement of disease activity. We devised a double-blind placebo pulse phase in which 19 of our 28 long-term patients participated in a study within a study lasting four weeks. They were divided into two groups. The first group took their usual dose of naproxen during the first two weeks and a corresponding number of placebo tablets in the next two weeks. The procedure was reversed in the other group. We conclude that naproxen remains efficacious.

Adult↗
PubMed1975

Naproxen and aspirin in rheumatoid arthritis: a multicenter double-blind crossover comparison study.

One hundred nineteen adults with active definite or classical rheumatoid arthritis were studied in a multicenter double-blind crossover study of naproxen (500 mg/day) and aspirin (3.6 Gm/day). Each drug was given in sequence for a six-week study period. Patients already receiving corticosteriod and/or gold therapy were maintained at constant dose throughout the study, but analgesics and other nonsteroidal antiinflammatory agents were discontinued at baseline. Objective and subjective evaluations by both investigator and patient were carried out at two-week intervals. No significant difference in global evaluation of efficacy or individual measures of efficacy was observed between aspirin and naproxen therapy, although physicians' global evaluation tended to favor naproxen. Sedimentation rate was lower on aspirin (naproxen 43.1 mm/hr; aspirin 38.7 mm/hr; P=0.02). Naproxen, 250 mg twice daily, was significantly better tolerated than aspirin, 900 mg four times daily. Mild, moderate, and severe side effects were less frequent with naproxen. The incidence of heartburn was significantly lower on naproxen, and significantly fewer patients terminated their six-week study period on naproxen than on aspirin. There were no significant deviations from baseline values in hematocrit, white cell or differential counts, or in tests of renal and hepatic function during the course of the study.

Anti-Inflammatory Agents↗
PubMed1975

Effect of naproxen on gastrointestinal microbleeding following acetylsalicylate medication.

This study was undertaken to determine if substitution of naproxen for ASA does influence salicylate-induced gastrointestinal bleeding. Twelve normal volunteers were selected and given increasing doses of salicylate until guaiac tests were consistently positive. Autologous labeling of their red blood cells with 51-Cr was used to quantitate the microbleeding. After two weeks on ASA, six subjects were double blindly switched to naproxen and six to placebo for another two weeks of observation. Two-way analysis of variance on the raw data shows a significant treatment effect associated with a significant interaction in both groups. Final analysis on a logarithmic scale permits orthogonal contrasts to be accurately made without any significant remaining interaction. It is concluded that substitution of naproxen for ASA at a dose of 500 mg daily is accompanied by a rapid reduction of microbleeding to "normal" levels.

Analysis of Variance↗
PubMed1975

Long-term clinical assessment of naproxen on rheumatoid arthritis patients and 51-Cr gastrointestinal bleeding on volunteers.

64 patients with rheumatoid arthritis (R.A.) entered the trial: 40 of them still remain on medication; 28 have so far completed 2 years; 23, 3 years; 12, 4 years using D-2-(6'-methoxy-2'-naphthyl)-propionic acid (naproxen) as the principal anti-inflammatory agent. Tolerance has been good: side effects or complaints, when reported, were mild and transient in nature. Close monitoring of a range of biochemical values by sequential laboratory studies has not revealed naproxen to have many adverse effects. After two years of daily continuous naproxen administration, 19 volunteer patients were subjected to a short-term double-blind cross-over placebo experiment. The results were in favor of a continued therapeutic efficacy of naproxen. The possible gastrointestinal bleeding found in the majority of anti-inflammatory drugs has been studied on 12 volunteers using 51-Cr. Naproxen exhibited a mean G.I. blood loss comparable to placebo or to physiological blood loss in normal volunteers. The conclusion drawn is that naproxen shows a good therapeutic index.

Adult↗